Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.61 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.61 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.61 |
| ▸ | GPR27 | Q9NS67 | 10/20 | 0.57 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14485217 | 0.89 | MAPK1 (0.61) | SLC10A2SLC10A1SLC10A6GPR27AVPR2 | |
| SCHEMBL30926557 | 0.81 | MEN1 (0.64) | GPR27MEN1KMT2AMAPT | |
| SCHEMBL27180923 | 0.81 | MEN1 (0.64) | GPR27MEN1KMT2AMAPT | |
| SCHEMBL27181624 | 0.79 | MAPT (0.80) | SLC10A2SLC10A1SLC10A6GPR27MEN1 | |
| SCHEMBL13875341 | 0.78 | L3MBTL1 (0.67) | MEN1KMT2AMAPK1MAPT | |
| SCHEMBL27181433 | 0.77 | CYP19A1 (0.60) | GPR27AVPR2MEN1KMT2AMAPT | |
| SCHEMBL30926996 | 0.77 | CYP19A1 (0.60) | GPR27AVPR2MEN1KMT2AMAPT | |
| SCHEMBL31610103 | 0.76 | MAPK1 (0.67) | SLC10A2SLC10A1SLC10A6GPR27AVPR2 | |
| SCHEMBL15848195 | 0.76 | MAPT (0.59) | GPR27AVPR2MEN1KMT2AMAPT | |
| SCHEMBL30926718 | 0.75 | ALDH1A1 (0.64) | GPR27AVPR2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070703-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | UNIV DREXEL (US) | 2021-03-11 | — | — | US | claimed |
| US-20190337891-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | UNIV DREXEL (US) | 2019-11-07 | — | — | US | claimed |
| EP-2726459-B1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | BARUCH S BLUMBERG INST (US) | 2019-09-11 | — | — | EP | claimed |
| WO-2019046287-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-03-07 | — | — | WO | claimed |
| US-20170320818-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | UNIV DREXEL (US) | 2017-11-09 | — | — | US | claimed |
| EP-3085368-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | Baruch S. Blumberg Institute (US) | 2016-10-26 | — | — | EP | claimed |
| US-9399619-B2 | Sulfamoylbenzamide derivatives as antiviral agents against HBV infection | BARUCH S. BLUMBERG INSTITUTE (US) | 2016-07-26 | — | — | US | claimed |
| US-20160101074-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE | 2016-04-14 | — | — | US | claimed |
| US-20140206666-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | Philadelphia Helath & Education Corporation d/b/a Drexel University College of Medicine (US) | 2014-07-24 | — | — | US | claimed |
| WO-2019046287-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-03-07 | — | — | WO | disclosed |
| EP-3085368-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | Baruch S. Blumberg Institute (US) | 2016-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160101074-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | ALKBH5, SULT1A1, SHMT1 | SLC10A2 537/4885SLC10A1 44/4885SLC10A6 1135/4885 |
| US-20170320818-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | ALKBH5, SULT1A1, SHMT1 | SLC10A2 537/4885SLC10A1 44/4885SLC10A6 1135/4885 |
| US-20190337891-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | ALKBH5, SULT1A1, SHMT1 | SLC10A2 537/4885SLC10A1 44/4885SLC10A6 1135/4885 |
| US-20210070703-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | ALKBH5, SULT1A1, SHMT1 | SLC10A2 537/4885SLC10A1 44/4885SLC10A6 1135/4885 |
| US-20140206666-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | HAVCR2, PHB1, BST2 | SLC10A2 94/4885SLC10A1 5/4885SLC10A6 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.